Best Manufacturer Anti Estrogen Steroids Raloxifene Hydrochloride Powder 82640-04-8

1.Quick Details:

Product Name: Raloxifene Hydrochloride

Synonyms: Raloxifene HCL

CAS: 82640-04-8

MF: C28H28ClNO4S

MW: 510.04

MP: 250-253°C

Storage temp: -20°C Freezer

Solubility DMSO:  28 mg/mL, soluble

Appearance: Light-Yellow Solid

2.Product Description:

Raloxifene hydrochlorideis an estrogen agonist/antagonist, commonly referred  to as a selective estrogen receptor modulator  (SERM) that belongs to the benzothiophene class of compounds.  Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4SHCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale yellow solid that  is very slightly  soluble in water.

EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 g of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrouslactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol,and titanium dioxide.

Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowingbone loss helps to reduce the risk of fractures.Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.This medication is not recommended for use in women before menopause. It should not be used in children...Side effect: Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, oreyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i.e., can cause developmental abnormalities such as birth defects.

3.Product Application:

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated. 

Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). 

Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.